Determinants of neuronal vulnerability in neurodegenerative diseases

Annals of Neurology

Volumn 44, Issue 3 SUPPL. 1, 1998, Pages

  Morrison, Brett M ^a   Hof, Patrick R ^a   Morrison, John H ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALZHEIMER DISEASE; AMYOTROPHIC LATERAL SCLEROSIS; ASSOCIATION CORTEX; CONFERENCE PAPER; DEGENERATIVE DISEASE; ENTORHINAL CORTEX; HUMAN; NERVE CELL; NEUROFILAMENT; NEUROPATHOLOGY; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; SPINAL CORD NERVE CELL;

EID: 0031668928     PISSN: 03645134     EISSN: None     Source Type: Journal    
DOI: 10.1002/ana.410440706     Document Type: Conference Paper

References (158)

1. Morrison JH. Differential vulnerability, connectivity, and cell typology. Neurobiol Aging 1993;14:51-54
2. Morrison JH, Lewis DA, Campbell MJ, et al. A monoclonal antibody to non-phosphorylated neurofilament protein marks the vulnerable cortical neurons in Alzheimer's disease. Brain Res 1987;416:331-336
3. Hof PR, Morrison JH. Quantitative analysis of a vulnerable subset of pyramidal neurons in Alzheimer's disease: II. Primary and secondary visual cortex. J Comp Neurol 1990;301:55-64
4. Hof PR, Cox K, Morrison JH. Quantitative analysis of a vulnerable subset of pyramidal neurons in Alzheimer's disease: I. Superior frontal and inferior temporal cortex. J Comp Neurol 1990;301:44-54
5. West MJ, Gundersen HJG. Unbiased stereological estimation of the number of neurons in the human hippocampus. J Comp Neurol 1990;296:1-22
6. Vickers JC, Delacourte A, Morrison JH. Progressive transformation of the cytoskeleton associated with normal aging and Alzheimer's disease. Brain Res 1992;594:273-278
7. West MJ. Regionally specific loss of neurons in the aging human hippocampus. Neurobiol Aging 1993;14:287-293
8. Hof PR, Morrison JH. The cellular basis of cortical disconnection in Alzheimer's disease and related dementing conditions. In: Terry R, Katzman R, Bick K, eds. Alzheimer's disease. New York: Raven Press, 1994:197-229
9. Vickers JC, Riederer BM, Marugg RA, et al. Alterations in neurofilament protein immunoreactivity in human hippocampal neurons related to normal aging and Alzheimer's disease. Neuroscience 1994;62:1-13
10. West MJ, Coleman PD, Flood DG, Troncoso JC. Differences in the pattern of hippocampal neuronal loss in normal ageing and Alzheimer's disease. Lancet 1994;344:769-772
11. Vickers JC, Chin D, Edwards AM, et al. Dystrophic neurite formation associated with age-related β amyloid deposition in the neocortex: clues to the genesis of neurofibrillary pathology. Exp Neurol 1996;141:1-11
12. Gómez-Isla T, Price JL, McKeel Jr DW, et al. Profound loss of layer II entorhinal cortex neurons occurs in very mild Alzheimer's disease. J Neurosci 1996;16:4491-4500
13. Gómez-Isla T, Hollister R, West H, et al. Neuronal loss correlates with but exceeds neurofibrillary tangles in Alzheimer's disease. Ann Neurol 1997;41:17-24
14. Morrison JH, Hof PR. Life and death of neurons in the aging brain. Science 1997;278:412-419
15. Simic G, Kostovic I, Winblad B, Bodganovic N. Volume and number of neurons of the human hippocampal formation in normal aging and Alzheimer's disease. J Comp Neurol 1997; 379:482-494
16. Vickers JC. A cellular mechanism for the neuronal changes underlying Alzheimer's disease. Neuroscience 1997;78:629-639
17. Braak H, Brank E. Ratio of pyramidal cells versus nonpyramidal cells in the human frontal isocortex and changes in ratio with ageing and Alzheimer's disease. In: Swaab DF, Fliers E, Mirmiran M, Van Gool VA, Van Haaren F, eds. Aging of the brain and Alzheimer's disease. Amsterdam: Elsevier, 1986:185-212
18. Giannakopoulos P, Hof PR, Kövari E, et al. Distinct patterns of neuronal loss and Alzheimer's disease lesion distribution in elderly individuals older than 90 years. J Neuropathol Exp Neurol 1996;55:1110-1120
19. Sternberger LA, Sternberger NH. Monoclonal antibodies distinguish phosphorylated and nonphosphorylated forms of neurofilaments in situ. Proc Natl Acad Sci USA 1983;80:6126-6130
20. Lee VM, Carden MJ, Schlaepfer WW, Trojanowski JQ. Monoclonal antibodies distinguish several differentially phosphorylated states of the two largest rat neurofilament subunits (NF-H and NF-M) and demonstrate their existence in the normal nervous system of adult rats. J Neurosci 1987;7:3474-3488
21. Dahl D, Labkovsky B, Bignami A. Neurofilament phosphorylation in axons and perikarya: immunofluorescence study of the rat spinal cord and dorsal root ganglia with monoclonal antibodies. J Comp Neurol 1988;271:445-450
22. Campbell MJ, Morrison JH. Monoclonal antibody to neurofilament protein (SMI-32) labels a subpopulation of pyramidal neurons in the human and monkey neocortex. J Comp Neurol 1989;282:191-205
23. Ksiezak-Reding H, Dickson DW, Davies P, Yen SH. Recognition of tau epitopes by anti-neurofilament antibodies that bind to Alzheimer neurofibrillary tangles. Proc Natl Acad Sci USA 1987;84:3410-3414
24. Zhang H, Sternberger NH, Rubinstein LJ, et al. Abnormal processing of multiple proteins in Alzheimer disease. Proc Natl Acad Sci USA 1989;86:8045-8049
25. Trojanowski JQ, Schmidt ML, Shin R-W, et al. Altered tau and neurofilament proteins in neurodegenerative diseases: diagnostic implications for Alzheimer's disease and Lewy body dementias. Brain Pathol 1993;3:45-54
26. Hof PR, Morrison JH. Neurofilament protein defines regional patterns of cortical organization in the macaque monkey visual system: a quantitative immunohistochemical analysis. J Comp Neurol 1995;352:161-186
27. Hof PR, Nimchinsky EA. Regional distribution of neurofilament and calcium-binding proteins in the cingulate cortex of the macaque monkey. Cereb Cortex 1992;2:456-467
28. Hof PR, Nimchinsky EA, Morrison JH. Neurochemical phenorype of corticocortical connections in the macaque monkey: quantitative analysis of a subset of neurofilament protein-immunoreactive projection neurons in frontal, parietal, temporal, and cingulate cortices. J Comp Neurol 1995;362:109-133
29. Nimchinsky EA, Vogt BA, Morrison JH, Hof PR. Spindle neurons of the human anterior cingulate cortex. J Comp Neurol 1995;355:27-37
30. Nimchinsky EA, Vogt BA, Morrison JH, Hof PR. Neurofilament and calcium-binding proteins in the human cingulate cortex. J Comp Neurol 1997;384:597-620
31. Campbell MJ, Hof PR, Morrison JH. A subpopulation of primate corticocortical neurons is distinguished by somatodendritic distribution of neurofilament protein. Brain Res 1991; 539:133-136
32. Hof PR, Ungerleider LG, Webster MJ, et al. Neurofilament protein is differentially distributed in subpopulations of corticocortical projection neurons in the macaque monkey visual pathways. J Comp Neurol 1996;376:112-127
33. Hof PR, Nimchinsky EA, Ungerleider LG, Morrison JH. Morphologic and neurochemical characteristics of corticocortical projections: emergence of circuit-specific features and relationships to degenerative changes in Alzheimer's disease. In: Hyman BT, Duyckaerts C, Christen Y, eds. Connections, cognition, and Alzheimer's disease. Berlin: Springer-Verlag, 1997: 59-82
34. Hof PR, Ungerleider LG, Adams MM, et al. Callosally-projecting neurons in the macaque monkey V1/V2 border are enriched in nonphosphorylated neurofilament protein. Vis Neurosci 1997;14:981-987
35. Nimchinsky EA, Hof PR, Young WG, Morrison JH. Neurochemical, morphologic and laminar characterization of cortical projection neurons in the cingulate motor areas of the macaque monkey. J Comp Neurol 1996;374:136-160
36. Choi DW, Koh J, Peters S. Pharmacology of glutamate neurotoxicity in cortical cell culture: attenuation by NMDA antagonists. J Neurosci 1988;8:185-196
37. Choi DW, Rothman SM. The role of glutamate neurotoxicity in hypoxic-ischemic neuronal death. Annu Rev Neurosci 1990;13:171-182
38. Choi DW. Cerebral hypoxia: some new approaches and unanswered questions. J Neurosci 1990;10:2493-2501
39. Meldrum B, Garthwaite J. Excitatory amino acid neurotoxicity and neurodegenerative disease. Trends Pharmacol Sci 1990;11:379-387
40. Olney JW. Excitotoxin-mediated neuron death in young and old age. In: Coleman P, Higgins G, Phelps C, eds. Molecular and cellular mechanisms of neuronal plasticity in normal aging and Alzheimer's disease. Amsterdam: Elsevier, 1990:37-51
41. Farooqui AA, Horrocks LA. Excitatory amino acid receptors, neural membrane phospholipid metabolism and neurological disorders. Brain Res Rev 1991;16:171-191
42. Meldrum B, Garthwaite J. Excitatory amino acid neurotoxicity and neurodegenerative diseases. Trends Pharmacol Sci 1991;11:54-61
43. Coyle JT, Puttfarcken P. Oxidative stress, glutamate, and neurodegenerative disorders. Science 1993;262:689-695
44. Francis PT, Sims NR, Procter AW, Bowen DM. Cortical pyramidal neurone loss may cause glutamatergic hypoactivity and cognitive impairment in Alzheimer's disease: investigative and therapeutic perspectives. J Neurochem 1993;61:1589-1594
45. DeFelipe J, Huntley GW, del Rio MR, et al. Microzonal decreases in the immunostaining for non-NMDA ionotropic excitatory amino acid receptor subunits GluR2/3 and GluR5/6/7 in the human epileptogenic neocortex. Brain Res 1994; 657:150-158
46. Ellison G. The N-methyl-D-aspartate antagonists phencyclidine, ketamine and dizocilpine as both behavioral and anatomical models of the dementias. Brain Res Rev 1995;20:250-267
47. Lipton SA, Rosenberg PA. Excitatory amino acids as a final common pathway for neurologic disorders. N Engl J Med 1995;330:613-622
48. Blümcke I, Beck H, Scheffler B, et al. Altered distribution of α-amino-3-hydroxy-5-methyl-4-isoxazole propionate receptor subunit GluR2(4) and N-methyl-D-aspartate receptor subunit NMDAR1 in the hippocampus of patients with temporal lobe epilepsy. Acta Neuropathol (Berl) 1996;92:576-587
49. Morrison JH, Siegel SJ, Gazzaley AH, Huntley GW. Glutamate receptors: emerging links between subunit proteins and specific excitatory circuits in primate hippocampus and neocortex. Neuroscientist 1996;2:272-283
50. Ottersen OP, Laake JH, Reichelt W, et al. Ischemic disruption of glutamate homeostasis in brain: quantitative immunocytochemical analyses. J Chem Neuroanat 1996;12:1-14
51. Weiss JH, Choi DW. Slow non-NMDA receptor mediated neurotoxicity and amyotrophic lateral sclerosis. In: Rowland LP, ed. Amyotrophic lateral sclerosis and other motor neuron diseases. New York: Raven Press, 1991:311-318
52. Choi DW. Ionic dependence of glutamate neurotoxicity. J Neurosci 1987;7:369-379
53. 2+ chelators reduce early excitotoxic and ischemic neuronal injury in vitro and in vivo. Neuron 1993;11:221-235
54. Szatkowski M, Atwell D. Triggering and execution of neuronal death in brain ischemia: two phases of glutamate release by different mechanisms. Trends Neurosci 1994;17:359-365
55. Orrenius S, Burkitt MJ, Kass GEN, et al. Calcium ions and oxidative cell injury. Ann Neurol 1992;32:S33-42
56. Sommer B, Kohler M, Sprengel R, Seeburg PH. RNA editing in brain controls a determinant of ion flow in glutamate-gated channels. Cell 1991;67:11-19
57. Verdoorn TA, Burnashev N, Monyer H, et al. Structural determinants of ion flow through recombinant glutamate receptor channels. Science 1991;252:1715-1718
58. Gasic GP, Heinemann S. Determinants of the calcium permeation of ligand-gated cation channels. Curr Opin Cell Biol 1992;4:670-677
59. Huntley GW, Vickers JC, Morrison JH. Cellular and synaptic localization of NMDA and non-NMDA receptor subunits in neocortex: organizational features related to cortical circuitry, function, and disease. Trends Neurosci 1994;17:536-543
60. Dewar D, Chalmers DT, Graham DI, McCulloch J. Glutamate metabotropic and AMPA binding sites are reduced in Alzheimer's disease: an autoradiographic study of the hippocampus. Brain Res 1991;553:58-64
61. Carlson MD, Penney JB Jr., Young AB. NMDA, AMPA, and benzodiazepine binding site changes in Alzheimer's disease visual cortex. Neurobiol Aging 1993;14:343-352
62. García-Ladona FJ, Palacios JM, Probst A, et al. Excitatory amino acid AMPA receptor mRNA localization in several regions of normal and neurological disease affected human brain. An in situ hybridization histochemistry study. Mol Brain Res 1994;21:75-84
63. Greenamyre JT, Maragos WF. Neurotransmitter receptors in Alzheimer disease. Cerebrovasc Brain Metab Rev 1993;5: 61-94
64. Ikonomovic MD, Mizukami K, Davies P, et al. The loss of GluR2(3) immunoreactivity precedes neurofibrillary tangle formation in the entorhinal cortex and hippocampus of Alzheimer brains. J Neuropathol Exp Neurol 1997;56:1018-1027
65. Armstrong DM, Ikonomovic MD, Sheffield R, Wenthold RJ. AMPA-selective glutamate receptor subtype immunoreactivity in the entorhinal cortex of non-demented elderly and patients with Alzheimer's disease. Brain Res 1994;639:207-216
66. Yasuda RP, Ikonomovic MD, Sheffield R, et al. Reduction of AMPA-selective glutamate receptor subunits in the entorhinal cortex of patients with Alzheimer's disease pathology: a biochemical study. Brain Res 1995;678:161-167
67. Armstrong DM, Ikonomovic MD. AMPA-selective glutamate receptor subtype immunoreactivity in the hippocampal dentate gyrus of patients with Alzheimer's disease - evidence for hippocampal plasticity. Mol Chem Neuropathol 1996;28: 59-64
68. De Boni U, Crapper McLachlan DR. Controlled induction of paired helical filaments of the Alzheimer type in cultured human neurons by glutamate and aspartate. J Neurol Sci 1985; 68:105-118
69. Sautière PE, Sindou P, Couratier P, et al. Tau antigenic changes induced by glutamate in rat primary culture model: a biochemical approach. Neurosci Lett 1992;140:206-210
70. Mattson MP, Cheng B, Davis D, et al. β-amyloid peptides destabilize calcium homeostasis and render human cortical neurons vulnerable to excitotoxicity. J Neurosci 1992;12:376-389
71. Yang Q, Wang S, Karlsson JE, et al. Phosphorylated and nonphosphorylated neurofilament proteins: distribution in the rat hippocampus and early changes after kainic acid induced seizures. J Chem Neuroanat 1995;9:217-228
72. Sindou P, Lesort M, Couratier P, et al. Glutamate increases tau phosphorylation in primary neuronal cultures from fetal rat cerebral cortex. Brain Res 1994;646:124-128
73. Kesslak JP, Yuan D, Neeper S, Cotman CW. Vulnerability of the hippocampus to kainate excitotoxicity. Neurosci Lett 1995;188:117-120
74. Couratier P, Lesort M, Sindou P, et al. Modifications of neuronal phosphorylated τ immunoreactivity induced by NMDA toxicity. Mol Chem Neuropathol 1996;27:259-264
75. Gottron F, Turetsky D, Choi D. SMI-32 antibody against non-phosphorylated neurofilaments identifies a subpopulation of cultured cortical neurons hypersensitive to kainate toxicity. Neurosci Lett 1995;194:1-4
76. Carriedo SG, Yin HZ, Weiss JH. Motor neurons are selectively vulnerable to AMPA/kainate receptor-mediated injury in vitro. J Neurosci 1996;16:4069-4079
77. Huntley GW, Vickers JC, Morrison JH. Quantitative localization of NMDAR1 receptor subunit immunoreactivity in inferotemporal and prefrontal association cortices of monkey and human. Brain Res 1997;749:245-262
78. Vickers JC, Huntley GW, Edwards AM, et al. Quantitative localization of AMPA/kainate and kainate glutamate receptor subunit immunoreactivity in neurochemically identified subpopulations of neurons in the prefrontal cortex of the macaque monkey. J Neurosci 1993;13:2982-2992
79. Ehlers MD, Fung ET, O'Brien RJ, Huganir RL. Splice variant-specific interaction of the NMDA receptor subunit NR1 with neuronal intermediate filaments. J Neurosci 1998; 18:720-730
80. Baimbridge KG, Celio MR, Rogers JH. Calcium-binding proteins in the nervous system. Trends Neurosci 1992;15:303-308
81. 2+-binding proteins in human neurodegenerative disorders. Trends Neurosci 1992; 15:259-264
82. Andressen C, Blümcke I, Celio MR. Calcium-binding proteins: selective markers of nerve cells. Cell Tissue Res 1993; 271:181-208
83. Alexianu ME, Ho B-K, Mohamed AH, et al. The role of calcium-binding proteins in selective motoneuron vulnerability in amyotrophic lateral sclerosis. Aim Neurol 1994;36:846-858
84. Iacopino AM, Quintero EM, Miller EK. Calbindin-D-28k: a potential neuroprotective protein. Neurodegeneration 1994;3: 1-20
85. Sampson VL, Morrison JH, Vickers JC. The cellular basis for the relative resistance of parvalbumin and calretinin immunoreactive neocortical neurons to the pathology of Alzheimer's disease. Exp Neurol 1997;154:295-302
86. Ferrer I, Soriano E, Tuñon T, et al. Parvalbumin immunoreactive neurons in normal human temporal neocortex and in patients with Alzheimer's disease. J Neurol Sci 1991;106:135-141
87. Ferrer I, Tuñon T, Serrano MT, et al. Calbindin D-28k and parvalbumin immunoreactivity in the frontal cortex in patients with frontal lobe dementia of non-Alzheimer type associated with amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry 1993;56:257-261
88. Hof PR, Cox K, Young WG, et al. Parvalbumin-immunoreactive neurons in the neocortex are resistant to degeneration in Alzheimer's disease. J Neuropathol Exp Neurol 1991;50: 451-462
89. Fonseca M, Soriano E, Ferrer I, et al. Chandelier cell axons identified by parvalbumin-immunoreactivity in the normal human temporal cortex and in Alzheimer's disease. Neuroscience 1993;55:1107-1116
90. Chan-Palay V, Zetzsche T, Höchli M. Parvalbumin neurons in the hippocampus in senile dementia of the Alzheimer type, Parkinson's disease and multi-infarct dementia. Dementia 1991;2:297-313
91. Solodkin A, Veldhuizen SD, Van Hoesen GW. Contingent vulnerability of entorhinal parvalbumin-containing neurons in Alzheimer's disease. J Neurosci 1996;16:3311-3321
92. Hof PR, Nimchinsky EA, Celio MR, et al. Calretinin-immunoreactive neocortical interneurons are unaffected in Alzheimer's disease. Neurosci Lett 1993;152:145-149
93. Fonseca M, Soriano E. Calretinin-immunoreactive neurons in the normal human temporal cortex and in Alzheimer's disease. Brain Res 1995;691:83-91
94. Brion JP, Résibois A. A subset of calretinin-positive neurons are abnormal in Alzheimer's disease. Acta Neuropathol (Berl) 1994;88:33-43
95. Ichimiya Y, Emson PC, Mountjoy CQ, et al. Loss of calbindin-28k immunoreactive neurones from the cortex in Alzheimer-type dementia. Brain Res 1988;475:156-159
96. Hof PR, Morrison JH. Neocortical neuronal subpopulations labeled by a monoclonal antibody to calbindin exhibit differential vulnerability in Alzheimer's disease. Exp Neurol 1991; 111:293-301
97. Nishiyama E, Ohwada J, Iwamoto N, Arai H. Selective loss of calbindin D28k-immunoreactive neurons in the cortical layer II in brains of Alzheimer's disease: a morphometric study. Neurosci Lett 1993;163:223-226
98. Hayes TL, Lewis DA. Nonphosphorylated neurofilament protein and calbindin immunoreactivity in layer III pyramidal neurons of human neocortex. Cereb Cortex 1992;2:56-67
99. Adams RD, Victor M, Ropper AH. Principles of neurology. New York: McGraw-Hill, 1997
100. Tandan R. Clinical features and differential diagnosis of classical motor neuron disease. In: Williams AC, ed. Motor neuron disease. London: Chapman and Hall, 1994:3-28
101. Hirano A, Kurland LT, Sayre GP. Familial amyotrophic lateral sclerosis. Arch Neurol 1967;16:232-243
102. Hirano A. Cytopathology of amyotrophic lateral sclerosis. In: Rowland LP, ed. Amyotrophic lateral sclerosis and other motor neuron diseases. New York: Raven Press, 1991:91-101
103. Leigh PN, Swash M. Cytoskeletal pathology in motor neuron disease. In: Rowland LP, ed. Amyotrophic lateral sclerosis and other motor neuron diseases. New York: Raven Press, 1991: 115-124
104. Schiffer D, Cordera S, Cavalla P, Migheli A. Reactive astrogliosis of the spinal cord in amyotrophic lateral sclerosis. J Neurol Sci 1996;139(Suppl):S27-33
105. Oyanagi K, Ikuta F, Horikawa Y. Evidence for sequential degeneration of the neurons in the intermediate zone of the spinal cord in amyotrophic lateral sclerosis: a topographic and quantitative investigation. Acta Neuropathol (Berl) 1989;77: 343-349
106. Terao S, Sobue G, Hashizume Y, et al. Disease-specific patterns of neuronal loss in the spinal ventral horn in amyotrophic lateral sclerosis, multiple system atrophy and X-linked recessive bulbospinal neuronopathy, with special reference to the loss of small neurons in the intermediate zone. J Neurol 1994; 241:196-203
107. Gurney ME, Pu H, Chiu AY, et al. Motor neuron degeneration in mice that express a human Cu,Zn superoxide dismutase mutation. Science 1994;264:1772-1775
108. Chiu AY, Zhai P, Dal Canto MC, et al. Age-dependent penetrance of disease in a transgenic mouse model of familial amyotrophic lateral sclerosis. Mol Cell Neurosci 1995;6:349-362
109. Ripps ME, Huntley GW, Hof PR, et al. Transgenic mice expressing an altered murine superoxide dismutase gene provide an animal model of amyotrophic lateral sclerosis. Proc Natl Acad Sci USA 1995;92:689-693
110. Wong PC, Pardo CA, Borchelt DR, et al. An adverse property of a familial ALS-linked SOD1 mutation causes motor neuron disease characterized by vacuolar degeneration of mitochondria. Neuron 1995;14:1105-1116
111. Morrison BM, Gordon JW, Ripps ME, Morrison JH. Quantitative immunocytochemical analysis of the spinal cord in G86R superoxide dismutase transgenic mice: neurochemical correlates of selective vulnerability. J Comp Neurol 1996;373: 619-631
112. Bruijn LI, Becher MW, Lee MK, et al. ALS-linked SOD1 mutant G85R mediates damage to astrocytes and promotes rapidly progressive disease with SOD1-containing inclusions. Neuron 1997;18:327-338
113. Kostic V, Gurney ME, Deng H-X, et al. Midbrain dopaminergic neuronal degeneration in a transgenic mouse model of familial amyotrophic lateral sclerosis. Ann Neurol 1997;41: 497-504
114. Morrison BM, Janssen WG, Gordon JW, Morrison JH. Time course of neuropathology in the spinal cord of G86R superoxide dismutase transgenic mice. J Comp Neurol 1998;391: 64-77
115. Wolf HK, Crain BJ, Siddique T. Degeneration of the substantia nigra in familial amyotrophic lateral sclerosis. Clin Neuropathol 1991;6:291-296
116. Pardo CA, Xu Z, Borchelt DR, et al. Superoxide dismutase is an abundant component in cell bodies, dendrites, and axons of motor neurons and in a subset of other neurons. Proc Natl Acad Sci USA 1995;92:954-958
117. Rosen DR, Siddique T, Patterson D, et al. Mutations in Cu/Zn superoxide dismutase are associated with familial amyotrophic lateral sclerosis. Nature 1993;362:59-62
118. Siddique T, Deng H-X. Genetics of amyotrophic lateral sclerosis. Hum Mol Genet 1996;5:1465-1470
119. Borchelt DR, Lee MK, Slunt HS, et al. Superoxide dismutase 1 with mutations linked to familial amyotrophic lateral sclerosis possesses significant activity. Proc Natl Acad Sci USA 1994;91:8292-8296
120. Tsuda T, Munthasser S, Fraser PE, et al. Analysis of the functional effects of a mutation in SOD1 associated with familial amyotrophic lateral sclerosis. Neuron 1994;13:727-736
121. Fujii J, Myint T, Seo HG, et al. Characterization of wild-type and amyotrophic lateral sclerosis-related mutant Cu,Zn-superoxide dismutases overproduced in baculovirus-infected insect cells. J Neurochem 1995;64:1456-1461
122. Reaume AG, Elliott JL, Hoffman EK, et al. Motor neurons in Cu/Zn superoxide dismutase-deficient mice develop normally but exhibit enhanced cell death after axonal injury. Nature Genet 1996;13:43-47
123. Perry TL, Hansen S, Jones K. Brain glutamate deficiency in amyotrophic lateral sclerosis. Neurology 1987;37:1845-1848
124. Plaitakis A, Caroscio JT. Abnormal glutamate metabolism in amyotrophic lateral sclerosis. Ann Neurol 1987;22:575-579
125. Plaitakis A, Constantakakis E, Smith J. The neuroexcitotoxic amino acids glutamate and aspartate are altered in the spinal cord and brain in amyotrophic lateral sclerosis. Ann Neurol 1988;24:446-449
126. Rothstein JD, Tsai G, Kuncl RW, et al. Abnormal excitatory amino acid metabolism in amyotrophic lateral sclerosis. Ann Neurol 1990;28:18-25
127. Rothstein JD, Martin LJ, Kuncl RW. Decreased glutamate transport by the brain and spinal cord in amyotrophic lateral sclerosis. N Engl J Med 1992;326:1464-1468
128. Rothstein JD, Van Kammen M, Levey AI, et al. Selective loss of glial glutamate transporter GLT-1 in amyotrophic lateral sclerosis. Ann Neurol 1995;38:73-84
129. Rothstein JD, Jin L, Dykes-Hoberg M, Kuncl RW. Chronic inhibition of glutamate uptake produces a model of slow neurotoxicity. Proc Natl Acad Sci USA 1993;90:6591-6595
130. Rothstein JD, Dykes-Hoberg M, Pardo CA, et al. Knockout of glutamate transporters reveals a major role for astroglial transport in excitotoxicity and clearance of glutamate. Neuron 1996;16:675-686
131. Lledo P-M, Somasundaram B, Morton AJ, et al. Stable transfection of calbindin-D28k into the GH3 cell line alters calcium currents and intracellular calcium homeostasis. Neuron 1992;9:943-954
132. Chard PS, Bleakman D, Christakos S, et al. Calcium buffering properties of calbindin D-28k and parvalbumin in rat sensory neurones. J Physiol 1993;472:341-357
133. Ikonomidou C, Qin Qin Y, Labruyere J, Olney JW. Motor neuron degeneration induced by excitotoxin agonists has features in common with those seen in the SOD-1 transgenic mouse model of amyotrophic lateral sclerosis. J Neuropathol Exp Neurol 1996;55:211-224
134. Hollmann M, O'Shea-Greenfield A, Rogers SW, Heinemann S. Cloning by functional expression of a member of the glutamate receptor family. Nature 1989;342:643-648
135. Boulter J, Hollmann M, O'Shea-Greenfield A, et al. Molecular cloning and functional expression of glutamate receptor subunit genes. Science 1990;249:1033-1037
136. Keinanen K, Wisden W, Sommer B, et al. A family of AMPA-selective glutamate receptors. Science 1990;249:556-560
137. Brose N, Huntley GW, Stern-Bach Y, et al. Differential assembly of coexpressed glutamate receptor subunits in neurons of rat cerebral cortex. J Biol Chem 1994;269:16780-16784
138. Puchalski RB, Louis J-C, Brose N, et al. Selective RNA editing and subunit assembly of native glutamate receptors. Neuron 1994;13:131-147
139. 2+ permeability of AMPA receptots in principal neurons and interneurons in rat CNS. Neuron 1995;15:193-204
140. 2+-permeable AMPA/kainate receptors and BAX expression [abstract]. Soc Neurosci Abstr 1997;23:2305
141. Sato K, Kiyama H, Tohyama M. The differential expression patterns of messenger RNAs encoding non-N-methyl-D-aspartate glutamate receptor subunits (GluR1-4) in the rat brain. Neuroscience 1993;52:515-539
142. Tolle TR, Berthele A, Zieglgansberger W, et al. The differential expression of 16 NMDA and non-NMDA receptor subunits in the rat spinal cord and in periaqueductal gray. J Neurosci 1993;13:5009-5028
143. Jakowec MW, Fox AJ, Martin LJ, Kalb RG. Quantitative and qualitative changes in AMPA receptor expression during spinal cord development. Neuroscience 1995;67:893-907
144. Jakowec MW, Yen L, Kalb RG. In situ hybridization analysis of AMPA receptor subunit gene expression in the developing rat spinal cord. Neuroscience 1995;67:909-920
145. Tolle TR, Berthele A, Zieglgansberger W, et al. Flip and flop variants of AMPA receptors in the rat lumbar spinal cord. Eur J Neurosci 1995;7:1414-1419
146. Temkin R, Lowe D, Jensen P, et al. Expression of glutamate receptor subunits in alpha-motoneurons. Mol Brain Res 1997; 52:38-45
147. Morrison BM, Janssen WGM, Gordon JW, Morrison JH. Light and electron microscopic distribution of the AMPA receptor subunit, GluR2, in the spinal cord of control and G86R mutant superoxide dismutase transgenic mice. J Comp Neurol 1998:395:523-534
148. Schmitt J, Dux E, Gissel C, Paschen W. Regional analysis of developmental changes in the extent of GluR6 mRNA editing in rat brain. Dev Brain Res 1996;91:153-157
149. Paschen W, Schmitt J, Gissel C, Dux E. Developmental changes of RNA editing of glutamate receptor subunits GluR5 and GluR6: in vivo versus in vitro. Dev Brain Res 1997;98: 271-280
150. Manetto V, Sternberger NH, Perry G, et al. Phosphorylation of neurofilaments is altered in amyotrophic lateral sclerosis. J Neuropathol Exp Neurol 1988;47:642-653
151. Munoz DG, Greene C, Perl DP, Selkoe DJ. Accumulation of phosphorylated neurofilaments in anterior horn motoneurons of amyotrophic lateral sclerosis patients. J Neuropathol Exp Neurol 1988;47:9-18
152. Mizusawa H, Matsumoto S, Yen S-H, et al. Focal accumulation of phosphorylated neurofilaments within anterior horn cell in familial amyotrophic lateral sclerosis. Acta Neuropathol (Berl) 1989;79:37-43
153. Troost D, Sillevis Smitt PAE, de Jong JMBV, Swaab DF. Neurofilament and glial alterations in the cerebral cortex in amyotrophic lateral sclerosis. Acta Neuropathol (Berl) 1992; 84:664-673
154. Côté F, Collard J-F, Julien J-P. Progressive neuronopathy in transgenic mice expressing the human neurofilament heavy gene: a mouse model of amyotrophic lateral sclerosis. Cell 1993;73:35-46
155. Xu Z, Cork LC, Griffin JW, Cleveland DW. Increased expression of neurofilament subunit NF-L produces morphological alterations that resemble the pathology of human motor neuron disease. Cell 1993;73:23-33
156. Lee MK, Marszalek JR, Cleveland DW. A mutant neurofilament subunit causes massive, selective motor neuron death: implication for the pathogenesis of human motor neuron disease. Neuron 1994;13:975-988
157. Hugon J, Vallat JM. Abnormal distribution of phosphorylated neurofilaments in neuronal degeneration induced by kainic acid. Neurosci Lett 1990;119:45-48
158. Vickers JC, Morrison JH, Friedrich Jr VL, et al. Age-associated and cell-type-specific neurofibrillary pathology in transgenic mice expressing the human mid-sized neurofilament subunit. J Neurosci 1994;14:5603-5612